Increased risk of intrauterine fetal death in women with fibroids

In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting -, in Chicago, researchers will unveil findings that show that there is an increased risk of intrauterine fetal death (IUFD), commonly known as stillbirth, in women who have fibroids.

IUFD, or still birth, is rare and affects only six to seven out of every thousand births.

The study, conducted by researchers at Washington University in St. Louis, Mo., identified women who had fibroids detected during their routine second trimester ultrasound for anatomic survey at 16-22 weeks.

"Fibroids are very common," said Dr. Molly J. Stout, one of the study's authors. "We think they occur in 5% to 20% of all women, but most women are asymptomatic and don't even know they have them."

The study was a retrospective cohort study of 64,047 women. Data were extracted on maternal sociodemographics, medical history, and obstetric outcomes. Pregnancies with any fetal anomalies were excluded. Women with at least one fibroid detected at the time of fetal anatomic survey were compared to women without fibroids. The primary outcome was IUFD after 20 weeks gestation. Univariate and multiple logistic regression analyses were used to estimate the risk of IUFD in women with fibroids, and subgroup was conducted by presence or absence of fetal growth restriction (IUGR).

The study found that of 64,047 women, the incidence of fibroids was 3.2%>

"Our results showed that women with a combination of fibroids and fetal growth restriction were at two-and-a-half times the risk of having a stillbirth, though the absolute risk remained rare," said Dr. Alison G. Cahill, another of the study's authors. "This may lead to a future recommendation for serial growth scans to monitor fetal growth in women with fibroids."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Patient-derived organoids: Transforming cancer research and personalized medicine